Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04440982 · ClinicalTrials.gov registry record · Phase 2
Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients
A Phase 2 study, sponsored by Lumicell.
- Terminated
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
NCT04440982: Clinical Trial Phase 2 study, sponsored by Lumicell.
NCT04440982 is a Phase 2 study that was terminated before completion, run by Lumicell. The registered enrollment target is 98 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04440982, a Phase 2 study, was terminated before completion, sponsored by Lumicell.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
Study Summary
This is a prospective, multi-center, randomized, clinical trial evaluating patients undergoing breast conserving surgery using the LUM Imaging System.
Primary Outcome
Refining of the previously validated tumor detection algorithm in breast cancer patients receiving neoadjuvant therapy will be conducted in the first cohort and the validation of this algorithm will use data from the second cohort.
Interventions
- DRUG LUM015
- DEVICE Lum Imaging System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2024-02-29 |
| Phase | Phase 2 |
Why NCT04440982 stopped before completion
NCT04440982 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 2 interventions - of which LUM015 is the first listed.
NCT04440982 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04440982 about?
NCT04440982 is a clinical study titled "Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients". This is a prospective, multi-center, randomized, clinical trial evaluating patients undergoing breast conserving surgery using the LUM Imaging System.
What is the current status of trial NCT04440982?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2020-09-01. Estimated completion is 2024-02-29.
What interventions are being tested in trial NCT04440982?
The interventions under investigation include: LUM015 (DRUG), Lum Imaging System (DEVICE).
Who is sponsoring clinical trial NCT04440982?
This trial is sponsored by Lumicell, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04440982's enrollment target sits among peer trials
98 743rd of 2000 higher than 1,255 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI